Comparative effectiveness of cardiovascular outcomes in new users of SGLT-2 inhibitors

Trial Identifier: D1690R00015
Sponsor: AstraZeneca
NCTID:: NCT02993614
Start Date: November 2017
Primary Completion Date: December 2020
Study Completion Date: December 2020
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Australia, D1690R00015 Melbourne, D1690R00015, Australia
Canada, D1690R00015 Mississauga, D1690R00015, Canada
Denmark, D1690R00015 Gentofte, D1690R00015, Denmark
Finland, D1690R00015 Espoo, D1690R00015, Finland
Germany, D1690R00015 Ulm, D1690R00015, Germany
Israel, D1690R00015 Raanana, D1690R00015, Israel
Italy, D1690R00015 Rome, D1690R00015, Italy
Japan, D1690R00015 Tokyo, D1690R00015, Japan
Norway, D1690R00015 Oslo, D1690R00015, Norway
Portugal, D1690R00015 Porto, D1690R00015, Portugal
Singapore, D1690R00015 Singapore, D1690R00015, Singapore
South Korea, D1690R00015 Seoul, D1690R00015, South Korea
Spain, D1690R00015 Madrid, D1690R00015, Spain
Sweden, D1690R00015 Sodertalje, D1690R00015, Sweden
Taiwan, D1690R00015 Taipei, D1690R00015, Taiwan
United Kingdom, D1690R00015 Luton, D1690R00015, United Kingdom
United States of America, Delaware Wilmington, Delaware, United States of America, 19850